You are here
|Discussion of RNA change on adding translation blocking Morpholino||
|Wednesday, January 18, 2023 - 12:35|
|History: exon skipping||
Lim, K.R.Q., Yokota, T. (2018). Invention and Early History of Exon Skipping and Splice Modulation. In: Yokota, T., Maruyama, R. (eds) Exon Skipping and Inclusion Therapies. Methods in Molecular Biology, vol 1828. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8651-4_1
|Tuesday, January 17, 2023 - 11:03|
|Master’s thesis based on microarray analysis of WT, Morphant and rescue fish||
Master’s thesis based on microarray analysis of WT, Morphant and rescue fish
|Monday, January 16, 2023 - 11:32|
|Vivo-Morpholino uptake by zebrafish larvae at 4dpf||
Liang H, Li Y, Li M, Zhou W, Chen J, Zhang Z, Yang Y, Ran C, Zhou Z. The effect and underlying mechanism of yeast β-glucan on antiviral resistance of zebrafish against spring viremia of carp virus infection. Front Immunol. 2022 Nov 3;13:1031962. doi: 10.3389/fimmu.2022.1031962. eCollection 2022.
|Monday, November 21, 2022 - 09:48|
|Vivo-Morpholinos as switching molecules for virally-delivered targets in mice||
The authors of this new paper use an engineered viral vector (AAV) to express a secreted antibody. They make a version where the antibody is out-of-frame and a Morpholino is used to skip an exon, bring the antibody in-frame and switch on its functional expression; the target is a payload of the AAV and the switching molecule is the Morpholino. This use of Morpholinos as switching molecules in engineered systems has great therapeutic potential. In the same paper, they controlled the expression of their AAV cargo with a Vivo-Morpholino after delivery into a mouse.
|Wednesday, August 10, 2022 - 12:14|
|Head-to-head comparisons, Morpholinos and Phosphorothioates||
Single Stranded Fully Modified-Phosphorothioate Oligonucleotides can Induce Structured Nuclear Inclusions, Alter Nuclear Protein Localization and Disturb the Transcriptome In Vitro.
Flynn LL, Li R, Pitout IL, Aung-Htut MT, Larcher LM, Cooper JAL, Greer KL, Hubbard A, Griffiths L, Bond CS, Wilton SD, Fox AH, Fletcher S.
Front Genet. 2022;13:791416. doi:10.3389/fgene.2022.791416
|Tuesday, April 19, 2022 - 10:15|
|Adverse Drug Reactions and Toxicity of the FDA-approved Antisense Oligonucleotide Drugs||
Adverse Drug Reactions and Toxicity of the FDA-approved Antisense Oligonucleotide Drugs.
|Thursday, March 24, 2022 - 14:08|
|Pharmacol & Tox of FDA-approved antisense||
Absorption, distribution, metabolism, and excretion of FDA-approved antisense oligonucleotide drugs.
|Tuesday, March 1, 2022 - 14:34|
|Electroporation protocol: Amaxa 4D X unit nucleofector system||
Goossens R, Aartsma-Rus A. In Vitro Delivery of PMOs in Myoblasts by Electroporation. Methods Mol Biol. 2022;2434:191-205. doi: 10.1007/978-1-0716-2010-6_12.
|Tuesday, March 1, 2022 - 08:50|
|Analysis of an apparent mutant/morphant disagreement||
Barthelson K, Baer L, Dong Y, Hand M, Pujic Z, Newman M, Goodhill GJ, Richards RI, Pederson SM, Lardelli M. Zebrafish Chromosome 14 Gene Differential Expression in the fmr1 (h u2787) Model of Fragile X Syndrome. Front Genet. 2021 May 31;12:625466. doi: 10.3389/fgene.2021.625466. eCollection 2021.
Interesting analysis of an apparent mutant/morphant disagreement finding no genetic compensation experimentally.
|Tuesday, February 8, 2022 - 14:24|